MA25917A1 - Derives d'acides propionique ayant des proprietes activantes de ppar-alpha. - Google Patents

Derives d'acides propionique ayant des proprietes activantes de ppar-alpha.

Info

Publication number
MA25917A1
MA25917A1 MA27091A MA27091A MA25917A1 MA 25917 A1 MA25917 A1 MA 25917A1 MA 27091 A MA27091 A MA 27091A MA 27091 A MA27091 A MA 27091A MA 25917 A1 MA25917 A1 MA 25917A1
Authority
MA
Morocco
Prior art keywords
ppar
alpha
propionic acid
acid derivatives
activating properties
Prior art date
Application number
MA27091A
Other languages
English (en)
Inventor
Klaus Urbahns
Michael Woltering
Susanne Nikolic
Josef Pernerstorfer
Berthold Hinzen
Elke Dittrich-Wengenroth
Hilmar Bischoff
Claudia Hirth-Dietrich
Klemens Lustig
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10124905A external-priority patent/DE10124905A1/de
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of MA25917A1 publication Critical patent/MA25917A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/18—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
MA27091A 2000-10-05 2003-04-04 Derives d'acides propionique ayant des proprietes activantes de ppar-alpha. MA25917A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10049208 2000-10-05
DE10124905A DE10124905A1 (de) 2000-10-05 2001-05-22 Propionsäurederivate

Publications (1)

Publication Number Publication Date
MA25917A1 true MA25917A1 (fr) 2003-10-01

Family

ID=26007267

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27091A MA25917A1 (fr) 2000-10-05 2003-04-04 Derives d'acides propionique ayant des proprietes activantes de ppar-alpha.

Country Status (22)

Country Link
EP (1) EP1328508A2 (fr)
JP (1) JP2004510757A (fr)
CN (1) CN1479716A (fr)
AU (1) AU2001293838A1 (fr)
BG (1) BG107684A (fr)
BR (1) BR0114437A (fr)
CA (1) CA2424540A1 (fr)
CZ (1) CZ2003964A3 (fr)
EE (1) EE200300140A (fr)
HN (1) HN2001000223A (fr)
HR (1) HRP20030346A2 (fr)
HU (1) HUP0302306A3 (fr)
IL (1) IL155125A0 (fr)
MA (1) MA25917A1 (fr)
MX (1) MXPA03002901A (fr)
NO (1) NO20031517L (fr)
NZ (1) NZ525119A (fr)
PL (1) PL361162A1 (fr)
RU (1) RU2003112968A (fr)
SK (1) SK4132003A3 (fr)
UY (1) UY26951A1 (fr)
WO (1) WO2002028821A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10151390A1 (de) * 2001-10-18 2003-05-08 Bayer Ag Essigsäurederivate
GB0214254D0 (en) * 2002-06-20 2002-07-31 Glaxo Group Ltd Chemical compounds
PT1554240E (pt) * 2002-10-21 2009-06-17 Janssen Pharmaceutica Nv Tetralinas e indanos substituídos e sua utilização
KR20050067419A (ko) * 2002-10-21 2005-07-01 얀센 파마슈티카 엔.브이. 치환된 테트라린 및 인단으로의 ｘ 증후군의 치료
RS20050318A (sr) * 2002-10-21 2007-09-21 Janssen Pharmaceutica N.V., Supstituisani tetralini i indani
EP1583754A1 (fr) * 2003-01-06 2005-10-12 Eli Lilly And Company Modulateurs du recepteur ppar
BRPI0413923A (pt) 2003-08-29 2006-11-07 Ono Pharmaceutical Co composto capaz de ligar o receptor de s1p e uso farmacêutico do mesmo
AR048931A1 (es) 2004-04-21 2006-06-14 Janssen Pharmaceutica Nv Proceso para la preparacion de derivados de tetralina sustituida e indano sustituido y preparacion de intermediarios de sintesis
CN100344618C (zh) 2004-05-24 2007-10-24 北京摩力克科技有限公司 作为hPPARα和hPPARγ激动剂的N－芳丙烯酰基取代的酪氨酸衍生物
KR100699928B1 (ko) * 2004-10-05 2007-03-26 재단법인서울대학교산학협력재단 퍼록시솜 증식자 활성화 수용체 알파 리간드를 제조하기위한 중간체의 제조방법
JP4318087B2 (ja) 2004-12-13 2009-08-19 小野薬品工業株式会社 アミノカルボン酸誘導体およびその医薬用途
CN101054372B (zh) * 2006-04-11 2010-10-13 中国科学院上海药物研究所 嘧啶取代苯丙酸衍生化合物、其制法和在治疗多囊肾疾病中的用途
JP5357894B2 (ja) 2008-12-01 2013-12-04 田辺三菱製薬株式会社 チアゾール環を含むカルボン酸誘導体およびその医薬用途
JP5436941B2 (ja) * 2009-06-03 2014-03-05 あすか製薬株式会社 ラクタム化合物又はその塩及びｐｐａｒ活性化剤
UY34200A (es) 2011-07-21 2013-02-28 Bayer Ip Gmbh 3-(fluorovinil)pirazoles y su uso
WO2016091746A1 (fr) * 2014-12-11 2016-06-16 Dsm Sinochem Pharmaceuticals Netherlands B.V. Procédé d'acylation d'un peptide cyclique

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2320387A1 (de) * 1973-04-21 1974-10-31 Boehringer Mannheim Gmbh Phenoxyalkylcarbonsaeurederivate und verfahren zur herstellung derselben
GB9822473D0 (en) * 1998-10-16 1998-12-09 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
HRP20030346A2 (en) 2005-04-30
RU2003112968A (ru) 2004-09-20
SK4132003A3 (en) 2004-02-03
BR0114437A (pt) 2003-07-01
HUP0302306A3 (en) 2005-02-28
WO2002028821A2 (fr) 2002-04-11
NO20031517L (no) 2003-05-28
PL361162A1 (en) 2004-09-20
IL155125A0 (en) 2003-10-31
NO20031517D0 (no) 2003-04-03
CA2424540A1 (fr) 2003-04-02
CZ2003964A3 (cs) 2003-08-13
HUP0302306A2 (hu) 2003-10-28
EE200300140A (et) 2003-08-15
WO2002028821A3 (fr) 2002-08-15
JP2004510757A (ja) 2004-04-08
EP1328508A2 (fr) 2003-07-23
NZ525119A (en) 2005-04-29
MXPA03002901A (es) 2003-10-15
AU2001293838A1 (en) 2002-04-15
UY26951A1 (es) 2002-06-20
CN1479716A (zh) 2004-03-03
BG107684A (bg) 2003-10-31
HN2001000223A (es) 2001-10-25

Similar Documents

Publication Publication Date Title
MA25875A1 (fr) Nouveaux derives de l'acide aminodicarboxylique presentant des proprietes pharmaceutiques.
FR20C1039I2 (fr) Derives de l'uk-2a
FR15C0086I2 (fr) Derives d'hydroxamate en tant qu'inhibiteurs de desacetylase
MA26812A1 (fr) Pyrimidine-2,4,6-triones inhibitrices de metalloproteinases
EP1494676A4 (fr) Derives de quinolaxine fusionnee comme inhibiteurs de l'activite d'akt
IS6448A (is) Bakteríuskæð 3-amónóqínazólin-2.4díon hrifefni
EP1496896A4 (fr) Inhibiteurs de l'activite akt
EP1496906A4 (fr) Inhibiteurs de l'activite de akt
EP1494675A4 (fr) Inhibiteurs de l'activite de akt
UY26082A1 (es) Derivados de 1,4-diazabiciclo [3.2.2] nonan-4-carboxilato y -carboxamidas, su preparacion y su aplicacion en terapeutica
AU2002236683A1 (en) Non-isotopic detection of osteoblastic activity in vivo using modified bisphosphonates
AU2002232439A1 (en) Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors
MXPA03004794A (es) Derivados de acido mandelico y su uso como inhibidores de trombina.
MA27083A1 (fr) Derives de nicotine ou d'isonicotine benzothiazole
SI1337521T1 (sl) Soli izotiazol-4-karboksamida in njihova uporaba kot antihiperproliferacijska sredstva
PT1177195E (pt) 1-amino-triazolo¬4,3-a|quinazolina-5-onas e/ou -5-tionas inibidoras de fosfodiesterases iv
PL357780A1 (en) Hydroxyphenyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatement of pain
EP1251863A4 (fr) 22 proteines humaines secretees
HUP0302306A3 (en) Propionic acid derivatives with ppar-alpha activating properties
FR2813084B1 (fr) Preparation de bacteries lactiques ayant une activite de biopurification
AU2002220735A1 (en) Substituted derivatives of aminofuran-2-yl-acetic acid and aminothien-2-yl-acetic acid and the use thereof for treating migraines and pain
AU2001235437A1 (en) Isothiazolecarboxylic acid derivatives and their use as microbicides
AR028607A1 (es) Derivados de 1,4-diazepan-2,5-diona
ATE345123T1 (de) Behandlung von angiogenesebezogenen krankheiten mit benzoyl phenylessigsäure derivaten
FR2807764B1 (fr) Mutants de bacteries lactiques surproducteurs d'exopolysaccharides